论文部分内容阅读
目的:通过观察ITP模型小鼠白细胞介素-3(IL-3)、白细胞介素-6(IL-6)、白细胞介素-11(IL-11)和转化生长因子(TGF-β1)在骨髓细胞中检测的含量变化,探讨这些因子含量变化与免疫性血小板减少性紫癜(ITP)发病之间存在的关系。方法:采用酶联免疫方法(ELISA法)检测ITP模型小鼠骨髓细胞中IL-3、IL-6、IL-11、TGF-β1含量变化。结果:与正常组比较,ITP模型小鼠骨髓细胞中IL-3、IL-6、IL-11、TGF-β1含量升高且有统计学意义(P<0.05)。结论:巨核细胞调控作用因子IL-3、IL-6、IL-11和TGF-β1参与了ITP的疾病周期,在其全程中呈现重要作用。紫癜康颗粒通过改变骨髓中IL-3、IL-6、IL-11、TGF-β1的含量,实现治疗本病的作用,为临床用药提供新途径。
Objective: To observe the effects of interleukin-3 (IL-3), interleukin-6 (IL-6), interleukin-11 (IL-11) and transforming growth factor (TGF-β1) Bone marrow cells detected content changes to explore the changes in these factors and the relationship between the incidence of immune thrombocytopenic purpura (ITP). Methods: The levels of IL-3, IL-6, IL-11 and TGF-β1 in bone marrow cells of ITP mice were detected by enzyme-linked immunosorbent assay (ELISA). Results: Compared with the normal group, the levels of IL-3, IL-6, IL-11 and TGF-β1 in bone marrow cells of ITP mice increased significantly (P <0.05). CONCLUSION: The regulatory factors of megakaryocyte, IL-3, IL-6, IL-11 and TGF-β1 are involved in the disease cycle of ITP and play an important role in the whole process. Ziqikang granule can change the content of IL-3, IL-6, IL-11 and TGF-β1 in bone marrow to achieve the treatment of this disease and provide a new way for clinical use.